NCT02516410View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation

PHASE3CompletedINTERVENTIONAL

Enrollment

168

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

June 7, 2016

Study Completion Date

June 7, 2016

Conditions

Cystic Fibrosis

Interventions

DRUG

VX-661 plus ivacaftor combination

DRUG

Ivacaftor

DRUG

Placebo (matched to VX-661 plus ivacaftor combination)

DRUG

Placebo (matched to ivacaftor)

Trial Locations (41)

Unknown

Birmingham

La Jolla

Los Angeles

Denver

Miami

Atlanta

Chicago

Indianapolis

New Orleans

Ann Arbor

Detroit

Minneapolis

Kansas City

Omaha

New York

Cincinnati

Memphis

Austin

Dallas

Richmond

Seattle

Spokane

Brisban

Chermside

Herston

Innsbruck

Westmead

Graz

Innsbruck

Salzburg

Vancouver

Montreal

Bron

Montpellier

Paris

Haifa

Hashomer

Jerusalem

Petah Tikva

Barcelona

Valencia

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT02516410 - A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation | Biotech Hunter | Biotech Hunter